Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

J Virol 2012 May 29;86(9):5304-13. Epub 2012 Feb 29.

Department of Surgery, Division of Neurosurgery, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Herpes simplex virus 1 (HSV-1) mutants that lack the γ(1)34.5 gene are unable to replicate in the central nervous system but maintain replication competence in dividing cell populations, such as those found in brain tumors. We have previously demonstrated that a γ(1)34.5-deleted HSV-1 expressing murine interleukin-12 (IL-12; M002) prolonged survival of immunocompetent mice in intracranial models of brain tumors. We hypothesized that M002 would be suitable for use in clinical trials for patients with malignant glioma. To test this hypothesis, we (i) compared the efficacy of M002 to three other HSV-1 mutants, R3659, R8306, and G207, in murine models of brain tumors, (ii) examined the safety and biodistribution of M002 in the HSV-1-sensitive primate Aotus nancymae following intracerebral inoculation, and (iii) determined whether murine IL-12 produced by M002 was capable of activating primate lymphocytes. Results are summarized as follows: (i) M002 demonstrated superior antitumor activity in two different murine brain tumor models compared to three other genetically engineered HSV-1 mutants; (ii) no significant clinical or magnetic resonance imaging evidence of toxicity was observed following direct inoculation of M002 into the right frontal lobes of A. nancymae; (iii) there was no histopathologic evidence of disease in A. nancymae 1 month or 5.5 years following direct inoculation; and (iv) murine IL-12 produced by M002 activates A. nancymae lymphocytes in vitro. We conclude that the safety and preclinical efficacy of M002 warrants the advancement of a Δγ(1)34.5 virus expressing IL-12 to phase I clinical trials for patients with recurrent malignant glioma.

Download full-text PDF

Source
http://jvi.asm.org/content/86/9/5304.full.pdf
Web Search
http://jvi.asm.org/content/early/2012/02/22/JVI.06998-11.ful
Web Search
http://jvi.asm.org/cgi/doi/10.1128/JVI.06998-11
Publisher Site
http://dx.doi.org/10.1128/JVI.06998-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347348PMC
May 2012
26 Reads

Publication Analysis

Top Keywords

brain tumors
12
hsv-1 mutants
12
m002
9
simplex virus
8
clinical trials
8
produced m002
8
direct inoculation
8
models brain
8
virus expressing
8
herpes simplex
8
trials patients
8
malignant glioma
8
genetically engineered
8
efficacy m002
8
il-12 produced
8
murine il-12
8
murine
5
capable activating
4
determined murine
4
m002 capable
4

References

(Supplied by CrossRef)
Interleukin-12 in anti-tumor immunity and immunotherapy
Colombo et al.
Cytokine Growth Factor Rev. 2002

Similar Publications